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ABSTRACT 
Amavata, is firstly introduced as an independent disease in Madhav Nidana. It is a disease 
of Madhyam roga marga as it affects Sandhi and Hridya marma. Though Ama and Vata 
are the two main predominant pathogenic factors but the disease also represents 
Tridoshic vitiation. The affliction of joints by Vata dosha in association with Ama shows 
that both play equal role of Dosha and Dushya in the causation of this disease. This study 
includes evaluate the effect of Trial drugs Punarnavadi churna with Anupana of Rasna 
Saptak Qwatha and Eranda taila on the signs and symptoms of Amavata and also to 
evaluate the effect of trial drug with a standard drug Singhanada Guggulu on the signs 
and symptoms of Amavata. In short we can say that, Amavata is the resultant of improper 
digestion or partially digestion of the food particles due to hypofunction of Gatharagni 
and also due to accumulation of mala in the body and it is also considered as Pratham 
doshadusti. It may be considered as partially or incomplete metabolized Dathu in case of 
Dhatvagni mandata. This study might be helpful in breakdown Samprapti of Amavata 
roga and give right way to patient of Amavata.  
KEYWORDS: Punarnavadi churna, Singhanada guggulu, Amavata, Rasna saptak qwatha. 
INTRODUCTION 
The substance, which is not properly 
digested, disintegrated, foul smelling, excessive 
in quantity, slimy in nature and produces 
stiffness of the whole body is known as Ama[1-2]. 
Not only the food taken in huge quantity but the 
qualities like Viruddha ahara, Guru, Ruksha, 
Vistambhi, Snigdha ahar and Agnimandata also 
cause [3] in the production of Ama. Consumption 
of food when individual is afflicted with mental 
upset due to Kama, Krodha, Lobha, Moha, 
Irshaya, Shoka, Bhaya, Lajja, Chinta, Mano 
Udvega, Manoglani [4] etc. are important factors 
responsible for cause of Agnimandyajanya ama. 
According to this etymology the word Ama along 
with Vata dosha is termed as Amavata[5]. This 
also indicates that the Ama and vata are the two 
main predominant factors in causing Amavata. 
When Prakupit vata and Ama simultaneously 
enters in the Kostha, Trika and Sandhi leading to 
stiffness of the body and Trika sandhi vedna. The 
symptom[6] like Trisna, Gaurava, Gatrastabdhata, 
Agnimandya, Apaka, Angamarda, Aruchi and 
Jwara are found in this disease. In modern era it 
is correlated with Rheumatoid Arthritis (RA)[7], 
inflammatory auto-immune disorders. It is the 
commonest among chronic inflammatory joint 
disease in which joints becomes swollen, painful 
and stiffness. The Trail drug Punarnavadi 
churna[8] with Anupana of Rasna saptak qwatha 
[9], Eranda taila[10] and Standard drug Singhanada 
guggulu[11] along with trail drug work on disease 
Amavata and breakdown the Samprapti of 
Amavata. 
MATERIAL AND METHODS 
Step 1: preparation of Punarnavadi churna, 
Rasna saptak qwatha and Singhanada guggulu 
Procedure 1: preparation of Punarnavadi churna 
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Materials 
 Punarnava (Boerhavia diffusa L), Guduchi 
(Tinospora cordifolia (Willd.) Hook.F. & 
Thoms.), Shunthi (Zingiber officinale Rosc.), 
Shatahva (Anethum sowa Kurz.), 
Vriddhadaruka (Argenia nervosa Burm.f.), 
Shati (Curcuma zedoaria (Christ.) Roscoe), 
Munditika (Sphaeranthus indicus L.) each drug 
taken in equal amount. 
METHOD  
 For the preparation of Punarnavadi Churna 
- Punarnava, Guduchi, Shunthi, Satahava, 
Vriddhadaruka, Sati and Munditika were taken in 
equal quantity and made into fine powder and 
kept in a neat and clean pot. 
Procedure 2: preparation of Rasna saptak 
qwatha 
Materials 
 Rasna (Pluchea lanceolata Oliver & Hiern.), 
Guduchi (Tinospora cordifolia (Willd.) Hook.F. 
& Thoms.), Erandmool (Ricinus communis L.), 
Devadaru (Cedrus deodara (roxb.) Loud.), 
Punarnava (Boerhavia diffusa L.), Gokharu 
(Tribulus terrestris L.), Aragvadha (Cassia 
fistula L.) each drug taken in equal amount. 
METHOD 
 For the preparation of the drug 
Rasnasaptak qwatha - Rasna, Guduchi, 
Erandmool, Dewadaru, Punarnava, Gokharu and 
Aragvadha were taken in equal quantity and 
made it into coarse power (yawakut) and made 
the qwatha with four times water. When the 
water is reduced by one fourth then Qwatha will 
be filtered. 
Procedure 3: preparation of Singhanada 
guggulu 
Materials 
 Erand Taila (Ricinus communis L.) - 600 gm, 
Suddha Gandhaka (Sulphur) - 150 gm, 
Suddha Gugglu (Commiphora mukul (Hook. 
Ex. Stocks) Engl.) - 150 gm, Amalaki 
(Phyllanthus emblica L.) -150 gm, Haritaki 
(Terminali chebula Retz. & Willd.) - 150 gm, 
Vibhitaki (Terminalia bellerica Roxb.) - 150 
gm and Water - 3 liters.  
METHOD  
For the preparation of Singhanada 
guggulu each Haritaki, Vibhitaki and Amlaki 
were to be boiled in an iron vessel with water 
and when decoction reduced to one fourth and 
filtered through cloth. Then Suddha gandhaka, 
Guggulu and Eranda taila were added to the 
decoction and stirring all with iron saddle. When 
the mass begins to solidify, then it was called 
Siddha (cooked). When the mass is slightly 
cooled made in to pills of four Rati (1gm approx.) 
each and kept in a neat and clean pot. 
Step 2: Clinical study 
In the present study, the patients had 
been selected from OPD, IPD of the Govt. Ayurved 
Hospital Rewa and referred from other health 
institutes or by any physician of Rewa or from 
other places. Total 60 Amavata patients were 
registered for study and these patients are 
divided into two groups (30 patients each 
group). But out of them four patients from Trial 
group and three patients from standard group 
were LAMA during the treatment. Lastly Trial 
completed on 26 patients in Trial group and 27 
patients in standard group. The treatment given 
to the patients was of two months and after that 
follows up the patients as possible.  
Trial group: Contains 26 patients; Treated with 
Punarnavadi churna with Anupana of Rasna 
saptak qwatha and Eranda taila (trial drugs). 
The patients of the Trial group had been given 
Punarnavadi churna in the dose of 3 to 6 grams 
with anupana of 30 to 50 ml. of Rasna saptaka 
qwatha and 10 to 20ml of Eranda tail in the 
morning and evening with empty stomach. 
Standard group: contains 27 patients; treated 
with one standard drug Singhanada guggul and 
with trial drugs. Singhanada guggulu had been 
given 1 tab. B.D. to the patient of Amavata after 
meal in the morning and in evening with the 
Trial drugs. 
CRITERIA FOR ASSESSMENT OF PATIENTS  
Diagnosis 
Pathological investigations regarding 
disease had also been done to support the 
diagnosis as well as to exclude the other 
pathology, such as Hb%, TLC, DLC, ESR, RA 
Factor, X-ray of the affected joints. The 
investigations had been done before and after 
the treatment as well as during the treatment to 
rule out other pathology were developing. 
Parameter with gradation Score of Amavata  
The score system adopted for the 
evaluation of signs and symptoms before and 
after the treatment of Amavata. The score for all 
the previously mentioned signs and symptoms of 
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Amavata were as follows, Absent-0, Mild-1, 
Moderate-2 and Severe-3.  
Criteria of Assessing Total Effect  
 After the completion of treatment of both 
groups, the Trial group and standard group of 
Amavata under study, were finally assessed and 
evaluated in terms of highly effective, moderate 
effective, mild effective and negligible. The 
procedure of assessment of total effect of 
therapy on both groups of patients was 
described as Highly Effective: In this category 
when the signs, symptoms and pathological 
abnormalities of Amavata reduced by 76 to 
100% were noted ++++ improvement and 
considered as highly effective. Moderate 
Effective: When signs, symptoms and 
pathological abnormalities were reduced by 51 
to 75% and noted +++ improvement thus 
considered to be moderate effective. Mild 
Effective: A relief of signs, symptoms and 
pathological abnormalities reduced by 26 to 
50% and noted ++ improvement thus considered 
to be mild effective. Negligible: If the signs, 
symptoms and pathological abnormalities were 
reduced by 25% or below and considered + 
improvement thus accepted as negligible. 
OBSERVATION  
Signs and Symptoms of Amavata of Trial 
Group  
1. Sandhi Shotha (Swelling over joints): In the 
study twenty six patients of Trial group before 
treatment the mean score of Sandhi Shotha 
was 1.538 with minimum 0 and maximum 3 
score. While after treatment the mean score of 
Sandhi Shotha was 0.423 with minimum 0 and 
maximum 1 score. The mean score of total 
relief was 1.115 (72.50%). In the comparative 
statistical study the SD, SE, “t” and “p” values 
were 0.6661, 0.1306, 8.499 and p <0.001 
respectively.  
2. Sandhi Shoola (Pain in joints): In the study 
twenty six patients of Trial group before 
treatment the mean score of Sandhi Shoola was 
1.961 with minimum 1 and maximum 3 score. 
While after treatment the mean score of Sandhi 
Shoola was 0.538 with minimum 0 and 
maximum 1 score. The mean score of total 
relief was 1.423 (72.54%). In the comparative 
statistical study the SD, SE, “t” and “p” values 
were 0.5038, 0.0988, 14.372 and p <0.001 
respectively.  
3. Agni Daurbalya (Poor digestive faculty of 
body): In the study twenty six patients of Trial 
group before treatment the mean score of Agni 
Daurbalya was 1.653 with minimum 0 and 
maximum 3 score. While after treatment the 
mean score of Agni Daurbalya was 0.076 with 
minimum 0 and maximum 1 score. The mean 
score of total relief was 1.577 (95.34%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.8086, 0.1585, 9.905 
and p <0.001 respectively. 
4. Praseka (Salivation): In the Trial group 
before treatment the mean score of Praseka 
was 0.461 with minimum 0 and maximum 2 
score. While after treatment the total means 
score of Praseka was 0.076 with minimum 0 
and maximum 1 score. The mean score of total 
relief was 0.385 (83.33%). In the comparative 
statistical study the SD, SE, “t” and “p” values 
were 0.4961, 0.0972, 3.909 and p <0.001 
respectively.  
5. Utsaha hani (Loss of enthusiasm): In the 
Trial group before treatment the mean score of 
Utsaha hani was 2.230 with minimum 1 and 
maximum 3 score. While after treatment the 
total mean score of Utsaha hani was 0.923 with 
minimum 0 and maximum 2 score. The mean 
score of total relief was 1.307 (58.62%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.7359, 0.1443, 9.009 
and p <0.001 respectively. 
6. Kukshi shoola (Abdominal colic): In the Trial 
group before treatment the mean score of 
Kukshi shoola was 0.538 with minimum 0 and 
maximum 1 score. While after treatment the 
mean score of Kukshi shoola was 0 with 
minimum 0 and maximum 0 score. The mean 
score of total relief was 0.538 (100%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.5084, 0.0997, 5.315 
and p <0.001 respectively. 
7. Malabaddhata (Constipation): In the Trial 
group before treatment the mean score of 
Malabaddhata was 2.384 with minimum 1and 
maximum 3 score. While after treatment the 
mean score of Malabaddhata was 0 with 
minimum 0 and maximum 0 score. The mean 
score of total relief was 2.384 (100%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.6288, 0.1233, 18.798 
and p <0.001 respectively. 
Signs and Symptoms of Amavata of 
Standard Group 
1. Sandhi Shotha (Swelling over joints): In the 
study twenty seven patients of Standard group 
before treatment the mean score of Sandhi 
Shotha was 1.592 with minimum 0 and 
maximum 3 score. While after treatment the 
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mean score of Sandhi Shotha was 0.296 with 
minimum 0 and maximum 1 score. The mean 
score of total relief was 1.296 (81.39%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.7240, 0.1393, 9.260 
and p <0.001 respectively.  
2. Sandhi Shoola (Pain in joints): In the study 
twenty seven patients of Standard group 
before treatment the mean score of Sandhi 
Shoola was 2.074 with minimum 1 and 
maximum 3 score. While after treatment the 
mean score of Sandhi Shoola was 0.370 with 
minimum 0 and maximum 1 score. The mean 
score of total relief was 1.704 (82.14%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.6085, 0.1171, 14.517 
and p <0.001 respectively. 
3. Agni Daurbalya (Poor digestive faculty of 
body): In the studied twenty seven patients of 
Standard group before treatment the mean 
score of Agni Daurbalya was 1.925 with 
minimum 1 and maximum 3 score. While after 
treatment the mean score of Agni Daurbalya 
was 0.148 with minimum 0 and maximum 1 
score. The mean score of total relief was 1.777 
(92.30%). In the comparative statistical study 
the SD, SE, “t” and “p” values were 0.5774, 
0.1111, 15.931 and p <0.001 respectively. 
4. Praseka (Salivation): In the Standard group 
before treatment the mean score of Praseka 
was 0.629 with minimum 0 and maximum 2 
score. While after treatment the mean score of 
Praseka was 0.037 with minimum 0 and 
maximum 1 score. The mean score of total 
relief was 0.592 (94.11%). In the comparative 
statistical study the SD, SE, “t” and “p” values 
were 0.5007, 0.0963, 6.126 and p <0.001 
respectively. 
5. Utsaha hani (Loss of enthusiasm): In the 
Standard group before treatment the mean 
score of Utsaha hani was 2.259 with minimum 
1 and maximum 3 score. While after 
treatment the total mean score of Utsaha hani 
was 0.592 with minimum 0 and maximum 1 
score. The mean score of total relief was 
1.667 (73.77%). In the comparative statistical 
study the SD, SE, “t” and “p” values were 
0.4804, 0.0924, 17.965 and p <0.001 
respectively. 
6. Kukshi shoola (Abdominal colic): In the 
Standard group before treatment the mean 
score of Kukshi shoola was 0.703 with 
minimum 0 and maximum 2 score. While 
after treatment the mean score of Kukshi 
shoola was 00 with minimum 0 and maximum 
0 score. The mean score of total relief was 
0.703 (100%). In the comparative statistical 
study the SD, SE, “t” and “p” values were 
0.5417, 0.1042, 6.717 and p <0.001 
respectively. 
7. Malabaddhata (Constipation): In the 
Standard group the mean score of 
Malabaddhata before treatment was 2.518 
with minimum 2 and maximum 3 score. While 
after treatment the total means score of 
Malabaddhata was 0.148 with minimum 0 
and maximum 1 score. The total mean score 
of relief was 2.370 (94.11%). In the 
comparative statistical study the SD, SE, “t” 
and “p” values were 0.5092, 0.0980, 25.612 
and p <0.001 respectively. 
 
Table 1: Statistical Values of TLC, DLC, Hb%, ESR, S. Uric Acid and Rh-Factor of Trial Group 
S. 
No. 
Investigation  Mean Score Differ-
ence of 
Mean 
SD SE ‘t’ value ‘p’ value Remarks 
BT AT 
1 Total Leucocyte 
count/cu.mm 
10309.23 9569.23 740 388.64 76.21 9.710 p<0.001 H.S. 
2. Differential Leucocyte 
count/cu.mm 
       
 Polymorphs 67.38 65.11 5.27 2.4903 0.4883 8.109 p<0.001 H.S. 
 Lymphocytes 28.53 31.19 2.66 2.9165 0.5719 7.186 p<0.001 H.S. 
 Moncytes 1.75 1.10 0.65 0.4408 0.0864 9.143 p<0.001 H.S. 
 Basophils 0.31 0.20 0.11 0.3459 0.0678 4.867 p<0.001 H.S. 
 Eosinophils 2.23 2.15 0.08 0.9766 0.1915 5.587 p<0.001 H.S. 
3. Haemoglobin % 11.12 12.72 1.60 0.2900 0.0568 28.697 p<0.001 H.S. 
4. ESR mm Ist hr 
Wintrobe 
Method 
32.65 15.96 16.69 4.6196 0.9059 18.423 p<0.001 H.S. 
5. S.Uric Acid mg/dl 4.80 4.58 0.22 0.2044 0.04008 9.498 p<0.001 H.S. 
6. Rh-factor 1U/ml 22.69 21.07 1.62 1.3789 0.2704 8.505 p<0.001 H.S. 
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Table 2: Statistical Values of TLC, DLC, Hb%, ESR, S.Uric Acid and Rh-Factor of Standard Group 
S. No. Investigation  Mean Score Differ-
ence of 
Mean 
SD SE ‘t’ value ‘p’ value Remarks 
BT AT 
1 Total 
Leucocyte 
count/cu.mm 
10596.29 9777.77 818.52 570.80 109.71 7.595 p<0.001 H.S. 
2. Differential Leucocyte 
count/cu.mm 
       
 Polymorphs 68.14 66.55 1.59 2.7210 0.5236 6.856 p<0.001 H.S. 
 Lymphocytes 28 29.66 1.66 1.8544 0.3568 8.8 p<0.001 H.S. 
 Moncytes 1.43 1.11 0.32 0.6107 0.1175 5.957 p<0.001 H.S. 
 Basophils 0.33 0.15 0.18 0.3633 0.0699 4.649 p<0.001 H.S. 
 Eosinophils 2.33 2.07 0.26 0.6751 0.1299 7.12 p<0.001 H.S. 
3. Haemoglobin 
% 
11.09 11.91 0.82 0.2571 0.4974 15.969 p<0.001 H.S. 
4. ESR mm Ist hr 
Wintrobe 
Method 
34.62 19.92 14.70 5.475 1.0536 13.952 p<0.001 H.S. 
5. Serum Uric 
Acid mg/dl 
4.70 4.31 0.39 0.2159 0.0414 11.980 p<0.001 H.S. 
6. Rh-factor 
IU/ml 
25.14 23.37 1.77 1.926 0.3706 6.988 p<0.001 H.S. 
Table 3: Total Score of an Individual Patient of Studied 53 Patients of Amavata 
 
 
 Trial Group Standard Group 
Total Score of an Individual Patient Total Score of an Individual Patient 
No. of 
Patients 
BT AT Relief Relief % BT AT Relief Relief % 
01 29 7 22 75.86% 28 9 19 67.85% 
02 27 5 22 81.48% 33 6 27 81.81% 
03 36 9 27 75% 38 6 32 84.21% 
04 34 7 27 79.41% 42 8 34 80.95% 
05 27 5 22 81.48% 29 5 24 82.75% 
06 26 6 20 76.92% 35 4 31 88.57% 
07 43 9 34 79.06% 36 6 30 83.33% 
08 30 7 23 76.66% 28 3 25 89.28% 
09 34 8 26 76.47% 29 4 25 86.20% 
10 32 10 22 68.75% 36 11 25 69.44% 
11 27 10 17 62.96% 35 9 26 74.28% 
12 23 7 16 69.56% 45 12 33 73.33% 
13 20 6 14 70% 36 6 30 83.33% 
14 27 5 22 81.48% 28 4 24 85.71% 
15 31 11 20 64.51% 37 8 29 78.37% 
16 21 8 13 61.90% 30 3 27 90% 
17 34 8 26 76.47% 49 13 36 73.46% 
18 38 7 31 81.57% 36 6 30 83.33% 
19 22 5 17 77.27% 41 3 38 92.68% 
20 49 17 32 65.30% 35 3 32 91.42% 
21 40 11 29 72.50% 34 7 27 79.41% 
22 22 5 17 77.27% 41 10 31 75.60% 
23 25 5 20 80% 35 6 29 82.85% 
24 35 10 25 71.42% 31 3 28 90.32% 
25 36 9 27 75% 38 7 31 81.57% 
26 25 6 19 76% 38 8 30 78.94% 
27     25 3 22 88% 
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Overall Effect of the Therapy on studied 53 Patients of 
Amavata 
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Table 4: Overall Effect of the Therapy on Studied 53 Patients of Amavata 
S. No. Assessment  Trial Group Standard Group 
No. of Patient Percentage No. of Patient Percentage 
1. No Improvement 0 0 0 0 
2. Mild Improvement 0 0 0 0 
3. Moderate Improvement 12 46.15% 06 22.22% 
4. Marked Improvement 14 53.85% 21 77.78% 
5. Cured  0 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
In the present study it is found that the 
trial drug Punarnavadi Churna with Anupana of 
Rasna saptak qwatha and Eranda taila and the 
Standard group drug Singhanada Guggulu with 
Punarnavadi Churna, Rasna saptak qwatha and 
Eranda taila were statistically highly significant 
(p<0.001) on the general symptoms Angamarda, 
Aruchi, Trishna, Alasya, Gaurava, Jvara, Apaka, 
Sunata anganama of Amavata. It is also observed 
that the Trial and Standard group drug both 
were statistically highly significant on Sandhi 
shotha (inflammation over joints) and Sandhi 
Shoola (pain in joints). It is found that the Trial 
and Standard group drug both were statistically 
highly significant (p<0.001) on the severe 
symptoms of Amavata except Murchha (fainting) 
i.e. Agni dourbalya, Praseka, Utsaha hani, Mukha 
vairasya, Daha, Bahumutrata, Kukshi Kathinyata, 
Kukshi shoola, Nidra-viparyaya, Chhardi, Bhrama, 
Murchha, Hridagraha, Malabaddhata, Sharira 
Jadata, Antrakujana and Anaha. As in regard to 
Mruchha the both group drugs were significant 
(p<0.01). In the present study it is found that the 
TLC and DLC of the maximum patients of both 
groups were within normal range. But in few 
patients the total leucocyte count and 
differential leucocytes count were increased, 
which after treatment by trial and standard 
group drug become normal and statistically 
found highly significant. It is also found that the 
trial and standard group drugs both were 
statistically highly significant (p<0.001) on the 
hemoglobin, ESR, Serum Uric acid and on RA 
factor. 
CONCLUSION 
Effect of Trial drug (Punarnavadi Churna 
with Anupana of Rasna saptak qwatha and 
Eranda taila). After consideration of overall 
effect of therapy showed moderate improvement 
46.15% and marked improvement 53.85% but 
no patient was totally cured. Effect of Standard 
group drug, (Trial drug along with Singhanada 
Guggulu) consideration of overall effect of 
therapy showed moderate improvement 22.22% 
and marked improvement 73.33% but no 
patients could be totally cured. On the basis of 
above observation, it can be said that the 
Standard group drug is more effective in 
comparison to Trial drug. We would like to say 
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that if a patient follow to avoid the above 
mentioned etiological factors and Apathya of 
Amavata, the formulation of Amavata will be 
broken easily with the help of treatment given 
by the Trial drug Punarnavadi churna with 
anupana of Rasna saptak qwatha and Eranda 
taila and with Standard group drug (Singhanada 
Guggulu along with Trial drug). The present 
research work regarding Amavata is having 
limitation of time, equipments, arrangement and 
other circumstances of this work has been 
performed only on the basis of Signs and 
Symptoms but not based on satisfactory bio-
chemical and radiological level.  
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CONTENT OF PUNARNAVADI CHURNA 
    
Punarnava                Guduchi         Shunthi    Shatahva  
 
 
Vriddhadaruka                               Sati                  Munditika 
 
CONTENT OF ANUPANA (RASNA SAPTAK QWATHA AND ERANDA TAIL) 
    
Rasna       Erandmool    Dewadaru         Gokharu  
 
    
Aragvadha          Punarnawa          Guduchi            Erand Taila 
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CONTENT OF SINGHANADA GUGGULU 
 
                
Erand Taila    Vibhitaki    Haritaki 
 
                
Amalaki      Guggulu      Gandhaka 
